San Francisco-based Unity Biotechnology launched a restructuring program to focus on cellular senescence in ophthalmology and neurology.

South San Francisco-based Unity Biotechnology reported that the 12-week results from the company’s Phase II study of UBX0101 in moderate-to-severe painful osteoarthritis (OA) of the knee failed to show improvement over placebo.

Tanezumab, a non-opioid drug developed by Pfizer and Eli Lilly, met the main goals of a late-stage study in which over half of patients reported a significant reduction in hip or knee osteoarthritis pain.

So-called arthroscopic knee surgery is becoming a less common treatment for adults with torn cartilage or painful arthritis as a growing body of evidence shows little benefit from these operations, a U.S. study suggests.

The FDA’s new draft guidance will guide drug and medical device manufacturers that aim to develop treatments for “the underlying pathophysiology and structural progression” of osteoarthritis.

An experimental osteoarthritis drug developed by Pfizer Inc. and Eli Lilly and Co. achieved its main goal of lowering pain in a late-stage clinical trial.

Sanofi hired John Reed, the former top scientist at oncology market leader Roche, to head the drugmaker’s group research operations.

Anika Therapeutics Inc. announced results from the company’s CINGAL 16-02 clinical trial, an active-comparator Phase III study being conducted to support U.S. registration.

Anika announced a research collaboration with the Institute of Integrative Biology at the University of Liverpool to develop an injectable mesenchymal stem cell therapy for osteoarthritis.

Pfizer Inc. is abandoning research to find new drugs aimed at treating Alzheimer’s and Parkinson’s disease.